In fi­nal piv­ot from can­cer to rare dis­ease, Agios of­floads its share of Tib­so­vo roy­al­ties for $131M

Al­most two years af­ter Agios sold its on­col­o­gy unit to French phar­ma Servi­er in a $1.8 bil­lion deal, Agios is let­ting go of its last link to one of its old med­i­cines.

Agios an­nounced Thurs­day that it went ahead and sold its rights to 5% roy­al­ties on US net sales of Servi­er’s Tib­so­vo (ivosi­denib) to Sagard Health­care Part­ners for a one-time pay­ment of $131.8 mil­lion. Agios had sold off its on­col­o­gy busi­ness, in­clud­ing Tib­so­vo, to the French phar­ma back in 2020, clos­ing the sale in ear­ly 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER